Join
Live feed
·
PRReleasevia Quantisnow
NRX Pharmaceuticals Inc. logo

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

ByQuantisnow·Wall Street's wire, on your screen.
NRXP· NRX Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NRXP (NRX Pharmaceuticals Inc.) and more on Quantisnow.